UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/577,008	08/07/2006	Toshiharu Suzuki	3749-0112PUS1	7226
	7590 01/27/201 ART KOLASCH & BI	EXAMINER		
PO BOX 747		CHERNYSHEV, OLGA N		
FALLS CHURCH, VA 22040-0747			ART UNIT	PAPER NUMBER
		1649		
			NOTIFICATION DATE	DELIVERY MODE
			01/27/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

mailroom@bskb.com

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/577,008	SUZUKI ET AL.	
Examiner	Art Unit	

	Olga N. Chernyshev	1649	
The MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence add	ress
THE REPLY FILED <u>04 January 2010</u> FAILS TO PLACE THIS A	APPLICATION IN CONDITION FOR	R ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apper for Continued Examination (RCE) in compliance with 37 Comperiods:	the same day as filing a Notice of a replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(dvisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	tension and the corresponding amount of the statutory period for reply origing than three months after the mailing date.	of the fee. The appropria nally set in the final Offic	ate extension fee e action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed w AMENDMENTS 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, by	out prior to the date of filing a brief	will not be entered be	031160
(a) They raise new issues that would require further core (b) They raise the issue of new matter (see NOTE belo	nsideration and/or search (see NO		cause
(c) They are not deemed to place the application in bet appeal; and/or		ducing or simplifying th	ne issues for
(d) ☐ They present additional claims without canceling a	corresponding number of finally reje	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).	21. San attached Nation of Nan Co.	mpliant Amandment (I	OTOL 224)
 Ine amendments are not in compliance with 37 CFR 1.12 Applicant's reply has overcome the following rejection(s): 	See Continuation Sheet.		,
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 	owable if submitted in a separate, t	timely filed amendmer	t canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is prov. The status of the claim(s) is (or will be) as follows:		l be entered and an ex	xplanation of
Claim(s) allowed: <u>20</u> .			
Claim(s) objected to: Claim(s) rejected: <u>10</u> .			
Claim(s) rejected. <u>70.</u> Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after er	ntry is below or attache	ed.
11. The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application in	condition for allowand	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). ((PTO/SB/08) Paper No(s)		
	/Olga N. Chernyshev/ Primary Examiner, Art U	Init 1649	

Continuation of 5. Applicant's reply has overcome the following rejection(s): 112, second, sections 8-14; 112, first, section 16; and 102(b), section 19 of Paper of 10/05/2009.

Continuation of 11. does NOT place the application in condition for allowance because: The request for consideration has been fully considered. At p. 3 of the Response, Applicant submits that "Claim 10 has been amended as suggested by the Examiner, i.e. to be drawn to the use of brain tissue samples and the specific peptide fragments". However, claim 10 has been amended to recite use that is not supported by the specification as filed. Specifically, the original rejection of record applied to claim 10, which outlines the allowable subject matter, reads as follows:

"16. Claims 7-12 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods of diagnosis of Alzheimer's disease (AD) by detecting specific fragments of Alcadein in brain tissue of a patient etc.", see paper of 07/07/08. The instant claim 10 expressly recites measurements of the levels of Alcadein fragments (peptides of SEQ ID NO: 4 to 12) and the specification fails to provide any support and guidance as how to practice the method as claimed because it is limited to demonstration of colocalization of Alcadein and APP in the brain of AD patients and absence of such colocalization in normal control samples. Therefore, claim 10 stands rejected as not being enabled under 112, first paragraph.

Claim 10, if directed to diagnostic method using samples of brain tissue to detect colocalization of specific fragments of the polypeptide of SEQ ID NO: 1 with APP, is enabled and appears to be free of prior art..